In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Bucks the Trend, with Early-Stage Deals

Executive Summary

Unlike many of its Big Pharma brethren, for Roche, preclinical and Phase I licensing has been a favored deal-making formula: collaborate with a small company on the development of a compound at or before clinical proof-of-concept, drive the program using its development expertise, and retain rights to follow-on products with which it can repeat the process, presumably having now lowered both compound and clinical risk. Its deal with Kosan is the latest example.

You may also be interested in...



Roche's Partners: Replacing, or Fuelling In-House R&D?

Partnering is a must for every drug firm these days. But Roche's reputation as a committed, yet hands-off development partner--forged in its relationship with Genentech--still sets it apart. Critics accuse the Swiss group of using partners to fill the gap in its own R&D; indeed, much of Roche's recent growth has come from others' drugs. Roche executives argue that you can't spot winners outside without a strong internal engine; that engine remains unproven. But point isn't whether Roche's own R&D is strong or weak. The point is, does it matter?

Antisoma Takes Refuge With Roche

Roche could easily have swallowed cash-poor Antisoma whole. But the Swiss group has instead bought rights to the UK biotech's entire clinical portfolio, hoping thereby to preserve Antisoma's creativity--rather like it has done with Genentech.

Big Pharma's Response to R&D Woes: More Early-Stage Compound Deals

The earnest tone of the discussions at this year's Pharmaceutical Strategic Alliances Conference reflected an increasingly common assumption among industry executives and insiders: the drug industry's growth problem isn't a merely cyclical issue. Declining productivity, a problem evident in biotech companies as well as Big Pharma, is to blame. Industry executives provided mixed opinions on how to best tackle this challenge, but both Pfizer and Bristol-Myers Squibb suggested a trend towards early-stage compound licensing.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel